ProPhase Labs (NASDAQ:PRPH) is a diversified medical science and technology company with a focus on developing innovative solutions across diagnostics, genomics, and biotechnology spaces. The company is committed to leveraging its expertise in molecular biology to create advancements in disease detection and analysis, aiming to improve patient outcomes and healthcare efficiency. Projects under ProPhase Labs' umbrella include the development of advanced diagnostic tests for infectious diseases and genomic testing services that provide critical insights for personalized medicine. Objectives for the company revolve around expanding its market presence through cutting-edge research, strategic partnerships, and the acquisition of complementary technologies to address pressing health challenges.